Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
5300 Memorial Drive, Suite 950, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 299 % -58.9%
Debt-to-equity 62 % +392%
Return On Equity -166 % -173%
Return On Assets -102 % -89.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3M shares -89.9%
Common Stock, Shares, Outstanding 3M shares -89.9%
Entity Public Float 16M USD -60%
Common Stock, Value, Issued 3K USD -90%
Weighted Average Number of Shares Outstanding, Basic 3.71M shares +86.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 19.9M USD +16.9%
General and Administrative Expense 8.88M USD -16.2%
Operating Income (Loss) -28.9M USD -4.16%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -30.2M USD -14.8%
Earnings Per Share, Basic -11.7 USD/shares +52.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.41M USD -61.7%
Assets, Current 11.6M USD -58%
Property, Plant and Equipment, Net 190K USD -15.6%
Operating Lease, Right-of-Use Asset 450K USD -17.7%
Assets 23.4M USD -40.8%
Accounts Payable, Current 2.55M USD +27%
Employee-related Liabilities, Current 1.51M USD +175%
Accrued Liabilities, Current 3.04M USD +61.9%
Liabilities, Current 5.59M USD +43.9%
Operating Lease, Liability, Noncurrent 390K USD -21.4%
Liabilities 15.9M USD +263%
Retained Earnings (Accumulated Deficit) -151M USD -24.8%
Stockholders' Equity Attributable to Parent 7.48M USD -78.7%
Liabilities and Equity 23.4M USD -40.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.72M USD -11.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 3M shares -89.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.73M USD -14.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.41M USD -61.7%
Deferred Tax Assets, Valuation Allowance 32.3M USD +25.7%
Deferred Tax Assets, Gross 32.4M USD +25.7%
Operating Lease, Liability 574K USD +27.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.1M USD -14.7%
Lessee, Operating Lease, Liability, to be Paid 712K USD +29.5%
Operating Lease, Liability, Current 116K USD +31.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 159K USD +45.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 146K USD -4.58%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 138K USD +39.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 164K USD +60.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD +43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 141K USD +34.3%
Operating Lease, Payments 130K USD -12.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 128K USD +2.4%
Deferred Tax Assets, Net of Valuation Allowance 112K USD +30.2%
Share-based Payment Arrangement, Expense 1.78M USD -12.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%